AKTS
Aktis Oncology, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
24.07
▲ 0.07 (0.29%)
MARKET · —
Price
Open
23.58
Prev close
24.00
Day high
24.87
Day low
24.00
Volume
221.26K
Market cap
—
P/E (TTM)
—
52W range
14.72 – 34.19
Trailing performance
Returnvs SPY
1W
-3.45%
-2.1%
1M
+0.25%
-3.5%
3M
+25.89%
+22.8%
6M
+27.35%
+16.3%
YTD
+7.46%
-4.8%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
24.44
-1.51% from price
SMA 20
23.72
+1.49% from price
SMA 50
25.20
-4.47% from price
SMA 100
22.15
+8.65% from price
SMA 200
—
—
EMA 12
24.26
-0.79% from price
EMA 26
24.28
-0.85% from price
EMA 50
23.97
+0.40% from price
RSI (14)
48.7
Neutral
MACD (12,26,9)
-0.02
Hist 0.12
ATR (14)
1.26
5.24% of price
Realised vol 30D
48.3%
Annualised
Bollinger upper
25.59
20, 2σ
Bollinger lower
21.84
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Risk profile
Beta vs SPY
1.60
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
48.3%
Annualised
Market vol 1Y
13.8%
SPY, annualised
Max drawdown 1Y
-32.2%
Peak to trough
Max drawdown 5Y
-32.2%
Peak to trough
ATR 14
1.26
5.24% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
MT Newswires · 3d ago
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
24/7 Wall St. · 3d ago
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target
MT Newswires · 3d ago
Aktis: Q2 Earnings Snapshot
Associated Press · 9d ago
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
GlobeNewswire · 9d ago
Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing
MT Newswires · 43d ago
Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing
MT Newswires · 43d ago
Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target
MT Newswires · 68d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.